|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000171791 |
Summary for BCL2 |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000171791 | Gene symbol | BCL2 |
| Gene name | BCL2 apoptosis regulator | |
| HGNC | 990 | |
| Entrez ID | 596 | |
| Gene type | protein_coding | |
| Synonyms | BCL2|Bcl-2|PPP1R50 | |
| UniProtAcc | P10415 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| ENSG00000171791 | BCL2 | DB01050 | Ibuprofen | SmallMoleculeDrug |
| ENSG00000171791 | BCL2 | DB01229 | Paclitaxel | SmallMoleculeDrug |
| ENSG00000171791 | BCL2 | DB01248 | Docetaxel | SmallMoleculeDrug |
| ENSG00000171791 | BCL2 | DB01367 | Rasagiline | SmallMoleculeDrug |
| ENSG00000171791 | BCL2 | DB05297 | Paclitaxel docosahexaenoic acid | SmallMoleculeDrug |
| ENSG00000171791 | BCL2 | DB06307 | Apoptone | SmallMoleculeDrug |
| ENSG00000171791 | BCL2 | DB06756 | Betaine | SmallMoleculeDrug |
| ENSG00000171791 | BCL2 | DB08871 | Eribulin | SmallMoleculeDrug |
| ENSG00000171791 | BCL2 | DB09213 | Dexibuprofen | SmallMoleculeDrug |
| ENSG00000171791 | BCL2 | DB11581 | Venetoclax | SmallMoleculeDrug |
| ENSG00000171791 | BCL2 | DB12191 | Obatoclax | SmallMoleculeDrug |
| ENSG00000171791 | BCL2 | DB12340 | Navitoclax | SmallMoleculeDrug |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
| ENSG00000171791 | BCL2 | DB01229 | Paclitaxel | SmallMoleculeDrug | Treat Breast Cancer,Non-Small Cell Lung Cancer,Pancreatic Cancer |
| ENSG00000171791 | BCL2 | DB01248 | Docetaxel | SmallMoleculeDrug | Treat Breast Cancer, Gastroesophageal Junction Cancer,Head and Neck Cancer,Non-Small Cell Lung Cancer,Prostate Cancer,Stomach (Gastric) Cancer |
| ENSG00000171791 | BCL2 | DB08871 | Eribulin | SmallMoleculeDrug | Treat Breast Cancer,Soft Tissue Sarcoma |
| ENSG00000171791 | BCL2 | DB11581 | Venetoclax | SmallMoleculeDrug | Acute Myeloid Leukemia (AML),Chronic Lymphocytic Leukemia (CLL),Non-Hodgkin Lymphoma |
Top |
Structure and expression level for BCL2 |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor female and normal female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| BCL2 | 2.94e+02 | -2.02e+00 | 3.45e-01 | -5.86e+00 | 4.70e-09 | 8.14e-08 | READ |
Top |
Sex-biased somatic mutation for BCL2 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for BCL2 |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| SARC | cg21602520 | chr18:63318147 | CGI:chr18:63318270-63321053 | promoter,exon,CDS,gene body | 3.05e-01 | 4.31e-01 | -4.62e+00 | 3.92e-06 | 2.60e-05 | -1.26e-01 |
| SARC | cg12090740 | chr18:63320825 | CGI:chr18:63318270-63321053 | promoter | 4.99e-01 | 3.93e-01 | 2.41e+00 | 1.60e-02 | 2.50e-02 | 1.06e-01 |
| ACC | cg12953669 | chr18:63320784 | CGI:chr18:63318270-63321053 | promoter | 4.38e-01 | 5.54e-01 | -2.21e+00 | 2.72e-02 | 4.00e-02 | -1.16e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| LUAD | cg14889643 | chr18:63318403 | CGI:chr18:63318270-63321053 | promoter,exon,CDS,gene body | 2.51e-01 | 1.05e-01 | 2.19e+00 | 2.85e-02 | 3.16e-02 | 1.46e-01 |
| LUSC | cg21602520 | chr18:63318147 | CGI:chr18:63318270-63321053 | promoter,exon,CDS,gene body | 3.39e-01 | 5.73e-01 | -3.83e+00 | 1.26e-04 | 7.73e-04 | -2.33e-01 |
| LUSC | cg12953669 | chr18:63320784 | CGI:chr18:63318270-63321053 | promoter | 2.47e-01 | 1.45e-01 | 3.58e+00 | 3.50e-04 | 1.33e-03 | 1.02e-01 |
| LUSC | cg24408313 | chr18:63321232 | CGI:chr18:63318270-63321053 | promoter | 3.50e-01 | 4.75e-01 | -3.40e+00 | 6.84e-04 | 2.02e-03 | -1.26e-01 |
| LIHC | cg21602520 | chr18:63318147 | CGI:chr18:63318270-63321053 | promoter,exon,CDS,gene body | 5.75e-01 | 4.25e-01 | 4.00e+00 | 6.30e-05 | 1.37e-04 | 1.50e-01 |
| KIRP | cg21602520 | chr18:63318147 | CGI:chr18:63318270-63321053 | promoter,exon,CDS,gene body | 1.73e-01 | 2.75e-01 | -5.32e+00 | 1.06e-07 | 8.80e-07 | -1.02e-01 |
| CHOL | cg21602520 | chr18:63318147 | CGI:chr18:63318270-63321053 | promoter,exon,CDS,gene body | 2.88e-01 | 4.26e-01 | -2.65e+00 | 7.96e-03 | 1.92e-02 | -1.38e-01 |
| CHOL | cg24408313 | chr18:63321232 | CGI:chr18:63318270-63321053 | promoter | 3.50e-01 | 4.70e-01 | -2.29e+00 | 2.23e-02 | 3.24e-02 | -1.21e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg21602520 | chr18:63318147 | CGI:chr18:63318270-63321053 | promoter,exon,CDS,gene body | 2.12e-01 | 3.19e-01 | -1.02e+01 | 1.51e-24 | 1.23e-23 | -1.07e-01 |
| BRCA | cg12090740 | chr18:63320825 | CGI:chr18:63318270-63321053 | promoter | 1.47e-01 | 2.81e-01 | -1.14e+01 | 3.85e-30 | 5.70e-29 | -1.33e-01 |
| BRCA | cg24408313 | chr18:63321232 | CGI:chr18:63318270-63321053 | promoter | 3.24e-01 | 5.51e-01 | -1.45e+01 | 1.85e-47 | 4.25e-44 | -2.27e-01 |
| LUAD | cg12090740 | chr18:63320825 | CGI:chr18:63318270-63321053 | promoter | 1.21e-01 | 2.23e-01 | -3.84e+00 | 1.23e-04 | 9.52e-04 | -1.02e-01 |
| HNSC | cg21602520 | chr18:63318147 | CGI:chr18:63318270-63321053 | promoter,exon,CDS,gene body | 4.71e-01 | 3.03e-01 | 2.42e+00 | 1.55e-02 | 2.37e-02 | 1.68e-01 |
| COAD | cg24740531 | chr18:63318499 | CGI:chr18:63318270-63321053 | promoter,exon,CDS,gene body | 1.37e-01 | 1.23e-02 | 3.57e+00 | 3.62e-04 | 1.47e-03 | 1.25e-01 |
| LIHC | cg11330108 | chr18:63318882 | CGI:chr18:63318270-63321053 | UTR,promoter,exon,gene body | 1.64e-01 | 3.04e-01 | -3.14e+00 | 1.67e-03 | 3.38e-03 | -1.40e-01 |
Top |
Exon skipping events with PSI in TCGA for BCL2 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Landscape of exon skipping events across multiple cancer types. |
 |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for BCL2 |
| ∗Please access CAeditome for RNA editing annotation. |
| Landscape of RNA editing events across multiple cancer types. |
 |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| LUAD | BCL2-001 | chr18_63252805_- | 1.62e-01 | 1.17e-01 | 2.12e+00 | 3.39e-02 | 4.42e-02 | 4.50e-02 |
| LUAD | BCL2-001 | chr18_63299876_- | 5.97e-01 | 7.42e-01 | -2.55e+00 | 1.08e-02 | 2.97e-02 | -1.45e-01 |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for BCL2 |
| TFs related to BCL2. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| LAML | ZNF334 | BCL2 | 4.35e+00 | 9.82e-01 | 3.31e+00 | 6.30e-03 | Male-biased |
| MESO | ARGFX | BCL2 | 4.07e+00 | 9.84e-01 | 2.55e+00 | 3.33e-03 | Male-biased |
| MESO | SOX5 | BCL2 | 4.04e+00 | 9.81e-01 | 2.67e+00 | 5.52e-03 | Male-biased |
| SKCM | ZNF334 | BCL2 | 4.29e+00 | 9.83e-01 | 2.41e+00 | 6.95e-04 | Male-biased |
| SKCM | ZNF79 | BCL2 | 4.29e+00 | 9.83e-01 | 2.52e+00 | 1.00e-03 | Male-biased |
| BCL2 related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for BCL2 |
| RBPs related to ES in BCL2. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| BCL2 related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs72943550 | chr18:63956404:A:G | - | 0.381177385547183 | 0.0094919959692194 | PCPG | Female-baised eQTL |
| rs72943554 | chr18:63957133:T:C | - | 0.380953813648425 | 0.00969650958821897 | PCPG | Female-baised eQTL |
| rs72943544 | chr18:63954734:C:T | - | 0.380019188771824 | 0.0102512463601998 | PCPG | Female-baised eQTL |
| rs17076548 | chr18:66664697:C:T | - | 0.186761028986261 | 0.0339628561692813 | READ | Female-baised eQTL |
| rs72940053 | chr18:66673740:A:G | - | 0.187507175868896 | 0.0415809381209629 | READ | Female-baised eQTL |
| rs72940033 | chr18:66662000:A:G | - | 0.180029500991836 | 0.0479908645045836 | READ | Female-baised eQTL |
| rs17076547 | chr18:66662868:C:G | - | 0.180029500991836 | 0.0479908645045836 | READ | Female-baised eQTL |
| rs17076550 | chr18:66665541:T:C | - | 0.180029500991836 | 0.0479908645045836 | READ | Female-baised eQTL |
| rs79603723 | chr18:54237887:A:G | - | 0.176212173183132 | 2.65166130399801e-05 | HNSC | Female-baised eQTL |
| rs76876634 | chr18:54238282:G:A | - | 0.173955770135388 | 0.000171510351725369 | HNSC | Female-baised eQTL |
| rs114864269 | chr18:54237084:A:C | - | 0.177893355657957 | 0.000347398049483348 | HNSC | Female-baised eQTL |
| rs11151991 | chr18:54797493:G:C | - | 0.168227523741356 | 0.00506223815648109 | HNSC | Female-baised eQTL |
| rs11877014 | chr18:54797852:T:G | - | 0.168227523741356 | 0.00506223815648109 | HNSC | Female-baised eQTL |
| rs41472148 | chr18:54773630:C:G | - | 0.155656311061056 | 0.00709351098033103 | HNSC | Female-baised eQTL |
| rs73960633 | chr18:54782406:T:C | - | 0.159487132247303 | 0.0220287886870664 | HNSC | Female-baised eQTL |
| rs9958683 | chr18:54740686:C:A | - | 0.129552378991781 | 0.0394174243575861 | HNSC | Female-baised eQTL |
| rs4891784 | chr18:69876590:A:G | - | 0.106588488512562 | 7.35347514946491e-06 | LUAD | Female-baised eQTL |
| rs114293040 | chr18:69880650:T:C | - | 0.103032397429957 | 1.53046345965057e-05 | LUAD | Female-baised eQTL |
| rs78057137 | chr18:69877496:A:G | - | 0.0962094895186167 | 5.05960613094475e-05 | LUAD | Female-baised eQTL |
| rs150910207 | chr18:69512624:G:A | - | 0.124847315951332 | 0.000139045205933335 | LUAD | Female-baised eQTL |
| rs17773175 | chr18:69512736:A:G | - | 0.124847315951332 | 0.000139045205933335 | LUAD | Female-baised eQTL |
| rs7242352 | chr18:68249226:G:T | - | -0.0953179668653864 | 0.00124741258504574 | LUAD | Female-baised eQTL |
| rs7242790 | chr18:68249011:T:G | - | -0.0950837171974768 | 0.00132039919505703 | LUAD | Female-baised eQTL |
| rs8090295 | chr18:68251834:C:T | - | -0.0950837171974768 | 0.00132039919505703 | LUAD | Female-baised eQTL |
| rs77690845 | chr18:54979941:C:T | - | 0.0863189413578672 | 0.00206114616006237 | LUAD | Female-baised eQTL |
| rs79501118 | chr18:54978104:G:A | - | 0.0862279030626993 | 0.00212468552484436 | LUAD | Female-baised eQTL |
| rs17081096 | chr18:69511608:A:G | - | 0.10973367273176 | 0.00236596267156755 | LUAD | Female-baised eQTL |
| rs78679166 | chr18:69511660:T:G | - | 0.10973367273176 | 0.00236596267156755 | LUAD | Female-baised eQTL |
| rs11660023 | chr18:61414787:T:G | - | 0.0451759943305691 | 0.00397685052447168 | LUAD | Female-baised eQTL |
| rs12965182 | chr18:61419528:T:C | - | 0.0441925805649406 | 0.00442839789675504 | LUAD | Female-baised eQTL |
| rs12966454 | chr18:61413373:A:G | - | 0.0447812249239504 | 0.00443853258300254 | LUAD | Female-baised eQTL |
| rs60562197 | chr18:70689889:G:A | - | 0.0825980090869013 | 0.0104801580834226 | LUAD | Female-baised eQTL |
| rs72953566 | chr18:68040647:A:T | - | 0.0636230952558501 | 0.0136226673885515 | LUAD | Female-baised eQTL |
| rs12967202 | chr18:61407631:T:C | - | 0.0400249323195533 | 0.0179154551753623 | LUAD | Female-baised eQTL |
| rs113960301 | chr18:68040711:A:T | - | 0.0611855988875471 | 0.0179588014423385 | LUAD | Female-baised eQTL |
| rs17065913 | chr18:59521006:T:A | - | 0.047600201254701 | 0.0181786937988151 | LUAD | Female-baised eQTL |
| rs60036948 | chr18:54517538:A:G | - | 0.0588612137658221 | 0.0192224530099394 | LUAD | Female-baised eQTL |
| rs1540061 | chr18:59516312:G:A | - | 0.0399010431249889 | 0.019439841916739 | LUAD | Female-baised eQTL |
| rs1608516 | chr18:54476736:A:T | - | 0.0568811666461113 | 0.0221079507123396 | LUAD | Female-baised eQTL |
| rs60473905 | chr18:60651438:G:A | - | 0.0635761041209718 | 0.0239181063406952 | LUAD | Female-baised eQTL |
| rs940312 | chr18:54509151:C:T | - | 0.0565948277554222 | 0.0266878172984737 | LUAD | Female-baised eQTL |
| rs112170460 | chr18:60648061:A:T | - | 0.0614526915085914 | 0.0276238425918027 | LUAD | Female-baised eQTL |
| rs145294062 | chr18:60648465:A:T | - | 0.0614526915085914 | 0.0276238425918027 | LUAD | Female-baised eQTL |
| rs606903 | chr18:59285996:G:T | - | -0.0579769117259895 | 0.0279402007418966 | LUAD | Female-baised eQTL |
| rs12960827 | chr18:54502333:C:T | - | 0.0545864890626866 | 0.0305058172466941 | LUAD | Female-baised eQTL |
| rs16958398 | chr18:54503846:A:C | - | 0.052142216751006 | 0.0350916888307412 | LUAD | Female-baised eQTL |
| rs17069698 | chr18:62277647:C:A | - | 0.085822245161601 | 0.0355400721635367 | LUAD | Female-baised eQTL |
| rs7244902 | chr18:59518111:A:G | - | 0.0370331627251126 | 0.0361995838299693 | LUAD | Female-baised eQTL |
| rs17080442 | chr18:69128781:G:A | - | 0.0479846885819169 | 0.0378754245806504 | LUAD | Female-baised eQTL |
| rs17181489 | chr18:65960310:G:A | - | 0.0371113864212951 | 0.0380343531738709 | LUAD | Female-baised eQTL |
| rs9964060 | chr18:60649112:C:T | - | 0.0589951113734642 | 0.038998613094265 | LUAD | Female-baised eQTL |
| rs11661894 | chr18:68038219:T:A | - | 0.0561004677872234 | 0.0396889971445081 | LUAD | Female-baised eQTL |
| rs9955355 | chr18:60649202:T:C | - | 0.0530060993500263 | 0.0406632451848679 | LUAD | Female-baised eQTL |
| rs9964716 | chr18:60649782:C:G | - | 0.0524966561680207 | 0.0423527978976785 | LUAD | Female-baised eQTL |
| rs9964053 | chr18:60649796:G:C | - | 0.0524966561680207 | 0.0423527978976785 | LUAD | Female-baised eQTL |
| rs9953558 | chr18:60649797:A:C | - | 0.0524966561680207 | 0.0423527978976785 | LUAD | Female-baised eQTL |
| rs113470899 | chr18:60648170:A:G | - | 0.0526850491125425 | 0.0433557040178481 | LUAD | Female-baised eQTL |
| rs9748487 | chr18:60648558:T:C | - | 0.0526850491125425 | 0.0433557040178481 | LUAD | Female-baised eQTL |
| rs9319965 | chr18:60648641:G:A | - | 0.0526850491125425 | 0.0433557040178481 | LUAD | Female-baised eQTL |
| rs9319966 | chr18:60648676:G:C | - | 0.0526850491125425 | 0.0433557040178481 | LUAD | Female-baised eQTL |
| rs12457194 | chr18:58342639:T:C | - | -0.0426364568363833 | 0.0453085641449177 | LUAD | Female-baised eQTL |
| rs368926462 | chr18:60647804:A:G | - | 0.0575797262520939 | 0.0460319836829035 | LUAD | Female-baised eQTL |
| rs111300123 | chr18:60648124:G:A | - | 0.0575797262520939 | 0.0460319836829035 | LUAD | Female-baised eQTL |
| rs9963763 | chr18:58526523:G:A | - | -0.0409251301232562 | 0.0491167454258095 | LUAD | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs8084902 | chr18:64363281:C:T | - | 0.0577036261760758 | 0.0464959447177353 | KIRC | Male-baised eQTL |
| rs143844152 | chr18:58431965:T:G | - | 0.0834265646237033 | 5.09598536627523e-05 | LUAD | Male-baised eQTL |
| rs4891591 | chr18:67074655:T:G | - | -0.0777503787024889 | 0.000938292374414595 | LUAD | Male-baised eQTL |
| rs60692529 | chr18:59078569:T:A | - | 0.0583512855623096 | 0.00330684584609487 | LUAD | Male-baised eQTL |
| rs2018485 | chr18:54798437:G:A | - | -0.056521906099776 | 0.0041644378248249 | LUAD | Male-baised eQTL |
| rs918837 | chr18:53886027:C:T | - | -0.05319608768342 | 0.00976258411724004 | LUAD | Male-baised eQTL |
| rs4611554 | chr18:73166066:G:A | - | 0.0557538888919131 | 0.0131936671989883 | LUAD | Male-baised eQTL |
| rs12326983 | chr18:61114535:G:A | - | 0.0511394643363863 | 0.0143922898187281 | LUAD | Male-baised eQTL |
| rs938456 | chr18:62555232:C:A | - | 0.0409143645691859 | 0.0293469519096565 | LUAD | Male-baised eQTL |
| rs12717060 | chr18:66822484:A:C | - | -0.039085919970464 | 0.0309726710665808 | LUAD | Male-baised eQTL |
| rs1559582 | chr18:73179523:C:G | - | 0.0504139673168685 | 0.0317441564295282 | LUAD | Male-baised eQTL |
| rs73969441 | chr18:73186291:A:G | - | 0.0504139673168685 | 0.0317441564295282 | LUAD | Male-baised eQTL |
| rs7238978 | chr18:73190224:C:T | - | 0.0504139673168685 | 0.0317441564295282 | LUAD | Male-baised eQTL |
| rs78195811 | chr18:73195078:G:C | - | 0.0504139673168685 | 0.0317441564295282 | LUAD | Male-baised eQTL |
| rs73963460 | chr18:62584994:G:A | - | 0.0396786355848522 | 0.0345074420149585 | LUAD | Male-baised eQTL |
| rs73963461 | chr18:62585063:C:G | - | 0.0396786355848522 | 0.0345074420149585 | LUAD | Male-baised eQTL |
| rs10871613 | chr18:67145059:G:T | - | 0.0528039742491605 | 0.0346761464948801 | LUAD | Male-baised eQTL |
| rs73964072 | chr18:64811527:A:G | - | 0.0606799739217546 | 0.0367320535385784 | LUAD | Male-baised eQTL |
| rs5021920 | chr18:64387630:G:A | - | -0.0531321720688202 | 0.0375162777390805 | LUAD | Male-baised eQTL |
| rs12958985 | chr18:58778915:C:A | - | 0.0376559143354763 | 0.0378016214293654 | LUAD | Male-baised eQTL |
| rs12957896 | chr18:58778917:G:T | - | 0.0376559143354763 | 0.0378016214293654 | LUAD | Male-baised eQTL |
| rs11663212 | chr18:58778025:C:A | - | 0.036330829186627 | 0.0457904655629407 | LUAD | Male-baised eQTL |
| rs7236560 | chr18:59001278:G:A | - | 0.0624133275190787 | 0.0179801795075237 | COAD | Male-baised eQTL |
| rs9954020 | chr18:59037707:C:T | - | 0.0777419998684089 | 0.0222619929209652 | COAD | Male-baised eQTL |
| rs9952079 | chr18:59012267:G:A | - | 0.0718359347589842 | 0.0367478763709373 | COAD | Male-baised eQTL |
| rs1523858 | chr18:54432748:C:A | - | -0.10147174852571 | 0.037725312866393 | COAD | Male-baised eQTL |
| rs2469031 | chr18:73081101:C:T | - | 0.0573741517121155 | 0.0396399843001536 | COAD | Male-baised eQTL |
| rs10502982 | chr18:53601407:G:C | - | -0.0845142253865747 | 0.0449139053774166 | COAD | Male-baised eQTL |
| rs2939403 | chr18:64629072:G:A | - | 0.0556012358462005 | 0.0483222868043813 | COAD | Male-baised eQTL |
| rs7231985 | chr18:70888084:C:A | - | 0.0545539723800756 | 0.0494953057924668 | COAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000171791 |
| CpG Site: cg24408313 | |
| Position to Gene: promoter | |
| Male Effect: -0.0759966231166426 | |
| Female Effect: - | |
 | Gene ID: ENSG00000171791 |
| CpG Site: cg27569829 | |
| Position to Gene: gene | |
| Male Effect: -0.267468092686063 | |
| Female Effect: - | |
 | Gene ID: ENSG00000171791 |
| CpG Site: cg27569829 | |
| Position to Gene: gene | |
| Male Effect: -0.272875896797835 | |
| Female Effect: - | |
 | Gene ID: ENSG00000171791 |
| CpG Site: cg25373630 | |
| Position to Gene: gene | |
| Male Effect: -0.297013601909105 | |
| Female Effect: - |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg24408313 | chr18:63321232 | promoter | -0.0759966231166426 | 3.24391967593988e-07 | -0.3983333071828646 | 6.730446916809295e-10 | LUAD |
| cg27569829 | chr18:63317252 | gene | -0.267468092686063 | 2.64172315553694e-09 | -0.38331626951709336 | 4.1064517388321275e-12 | BLCA |
| cg27569829 | chr18:63317252 | gene | -0.272875896797835 | 1.20975839538616e-17 | -0.4634761856346531 | 5.370647721290895e-21 | HNSC |
| cg25373630 | chr18:63317423 | gene | -0.297013601909105 | 2.11502899053795e-15 | -0.43860918126124626 | 3.596782947776646e-18 | HNSC |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of BCL2 |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
| ENSG00000171791 | BCL2 | C0001418 | Adenocarcinoma | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0001430 | Adenoma | 2 | CTD_human |
| ENSG00000171791 | BCL2 | C0002152 | Alloxan Diabetes | 2 | CTD_human |
| ENSG00000171791 | BCL2 | C0002395 | Alzheimer's Disease | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0004096 | Asthma | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0004352 | Autistic Disorder | 2 | CTD_human |
| ENSG00000171791 | BCL2 | C0004509 | Azoospermia | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0005586 | Bipolar Disorder | 3 | PSYGENET |
| ENSG00000171791 | BCL2 | C0006142 | Malignant neoplasm of breast | 3 | CTD_human |
| ENSG00000171791 | BCL2 | C0007097 | Carcinoma | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0007102 | Malignant tumor of colon | 3 | CTD_human |
| ENSG00000171791 | BCL2 | C0007621 | Neoplastic Cell Transformation | 3 | CTD_human |
| ENSG00000171791 | BCL2 | C0009375 | Colonic Neoplasms | 3 | CTD_human |
| ENSG00000171791 | BCL2 | C0009402 | Colorectal Carcinoma | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0009404 | Colorectal Neoplasms | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0011265 | Presenile dementia | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0011581 | Depressive disorder | 5 | PSYGENET |
| ENSG00000171791 | BCL2 | C0011616 | Contact Dermatitis | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0011853 | Diabetes Mellitus, Experimental | 2 | CTD_human |
| ENSG00000171791 | BCL2 | C0011860 | Diabetes Mellitus, Non-Insulin-Dependent | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0013366 | Dyschondroplasias | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0014859 | Esophageal Neoplasms | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0015923 | Fetal Alcohol Syndrome | 2 | PSYGENET |
| ENSG00000171791 | BCL2 | C0016978 | gallbladder neoplasm | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0018671 | Head and Neck Neoplasms | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0018675 | Head Neoplasms | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0019207 | Hepatoma, Morris | 2 | CTD_human |
| ENSG00000171791 | BCL2 | C0019208 | Hepatoma, Novikoff | 2 | CTD_human |
| ENSG00000171791 | BCL2 | C0020538 | Hypertensive disease | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0021364 | Male infertility | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0021841 | Intestinal Neoplasms | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0023186 | Learning Disorders | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0023434 | Chronic Lymphocytic Leukemia | 2 | CTD_human |
| ENSG00000171791 | BCL2 | C0023467 | Leukemia, Myelocytic, Acute | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0023891 | Liver Cirrhosis, Alcoholic | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0023904 | Liver Neoplasms, Experimental | 2 | CTD_human |
| ENSG00000171791 | BCL2 | C0024301 | Lymphoma, Follicular | 2 | CTD_human |
| ENSG00000171791 | BCL2 | C0024302 | Reticulosarcoma | 2 | CTD_human |
| ENSG00000171791 | BCL2 | C0024304 | Lymphoma, Mixed-Cell | 2 | CTD_human |
| ENSG00000171791 | BCL2 | C0024305 | Lymphoma, Non-Hodgkin | 2 | CTD_human |
| ENSG00000171791 | BCL2 | C0024306 | Lymphoma, Undifferentiated | 2 | CTD_human |
| ENSG00000171791 | BCL2 | C0025237 | Melnick-Needles Syndrome | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0025261 | Memory Disorders | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0025568 | Metaplasia | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0026760 | Multiple Epiphyseal Dysplasia | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0026764 | Multiple Myeloma | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0026998 | Acute Myeloid Leukemia, M1 | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0027051 | Myocardial Infarction | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0027533 | Neck Neoplasms | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0027540 | Necrosis | 2 | CTD_human |
| ENSG00000171791 | BCL2 | C0027746 | Nerve Degeneration | 2 | CTD_human |
| ENSG00000171791 | BCL2 | C0029422 | Osteochondrodysplasias | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0032460 | Polycystic Ovary Syndrome | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0033578 | Prostatic Neoplasms | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0035126 | Reperfusion Injury | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0035304 | Retinal Degeneration | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0036341 | Schizophrenia | 2 | PSYGENET |
| ENSG00000171791 | BCL2 | C0036391 | Schwartz-Jampel Syndrome | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0037579 | Soft Tissue Neoplasms | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0038015 | Spondyloepiphyseal Dysplasia | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0038433 | Streptozotocin Diabetes | 2 | CTD_human |
| ENSG00000171791 | BCL2 | C0039101 | synovial sarcoma | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0079740 | High Grade Lymphoma (neoplasm) | 2 | CTD_human |
| ENSG00000171791 | BCL2 | C0079741 | Lymphoma, Intermediate-Grade | 2 | CTD_human |
| ENSG00000171791 | BCL2 | C0079744 | Diffuse Large B-Cell Lymphoma | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0079745 | Lymphoma, Large-Cell, Follicular | 2 | CTD_human |
| ENSG00000171791 | BCL2 | C0079747 | Low Grade Lymphoma (neoplasm) | 2 | CTD_human |
| ENSG00000171791 | BCL2 | C0079757 | Diffuse Mixed-Cell Lymphoma | 2 | CTD_human |
| ENSG00000171791 | BCL2 | C0079758 | Lymphoma, Mixed-Cell, Follicular | 2 | CTD_human |
| ENSG00000171791 | BCL2 | C0079765 | Lymphoma, Small Cleaved-Cell, Follicular | 2 | CTD_human |
| ENSG00000171791 | BCL2 | C0079770 | Lymphoma, Small Noncleaved-Cell | 2 | CTD_human |
| ENSG00000171791 | BCL2 | C0086404 | Experimental Hepatoma | 2 | CTD_human |
| ENSG00000171791 | BCL2 | C0153452 | Malignant neoplasm of gallbladder | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0162351 | Contact hypersensitivity | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0162820 | Dermatitis, Allergic Contact | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0205641 | Adenocarcinoma, Basal Cell | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0205642 | Adenocarcinoma, Oxyphilic | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0205643 | Carcinoma, Cribriform | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0205644 | Carcinoma, Granular Cell | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0205645 | Adenocarcinoma, Tubular | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0205646 | Adenoma, Basal Cell | 2 | CTD_human |
| ENSG00000171791 | BCL2 | C0205647 | Follicular adenoma | 2 | CTD_human |
| ENSG00000171791 | BCL2 | C0205648 | Adenoma, Microcystic | 2 | CTD_human |
| ENSG00000171791 | BCL2 | C0205649 | Adenoma, Monomorphic | 2 | CTD_human |
| ENSG00000171791 | BCL2 | C0205650 | Papillary adenoma | 2 | CTD_human |
| ENSG00000171791 | BCL2 | C0205651 | Adenoma, Trabecular | 2 | CTD_human |
| ENSG00000171791 | BCL2 | C0205696 | Anaplastic carcinoma | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0205697 | Carcinoma, Spindle-Cell | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0205698 | Undifferentiated carcinoma | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0205699 | Carcinomatosis | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0206637 | Mesenchymal Chondrosarcoma | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0206681 | Adenocarcinoma, Clear Cell | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0233794 | Memory impairment | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0235874 | Disease Exacerbation | 2 | CTD_human |
| ENSG00000171791 | BCL2 | C0242350 | Erectile dysfunction | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0276496 | Familial Alzheimer Disease (FAD) | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0276535 | AIDS with Kaposi's sarcoma | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0278996 | Malignant Head and Neck Neoplasm | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0345967 | Malignant mesothelioma | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0346627 | Intestinal Cancer | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0376358 | Malignant neoplasm of prostate | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0432272 | Van Buchem disease | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0494463 | Alzheimer Disease, Late Onset | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0546126 | Acute Confusional Senile Dementia | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0546837 | Malignant neoplasm of esophagus | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0678222 | Breast Carcinoma | 3 | CTD_human |
| ENSG00000171791 | BCL2 | C0746787 | Cancer of Neck | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0750900 | Alzheimer's Disease, Focal Onset | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0750901 | Alzheimer Disease, Early Onset | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0751177 | Cancer of Head | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0751262 | Adult Learning Disorders | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0751263 | Learning Disturbance | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0751265 | Learning Disabilities | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0751292 | Age-Related Memory Disorders | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0751293 | Memory Disorder, Semantic | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0751294 | Memory Disorder, Spatial | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0751295 | Memory Loss | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0848676 | Subfertility, Male | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0853193 | Bipolar I disorder | 2 | PSYGENET |
| ENSG00000171791 | BCL2 | C0887900 | Upper Aerodigestive Tract Neoplasms | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C0917731 | Male sterility | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C1136382 | Sclerocystic Ovaries | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C1257931 | Mammary Neoplasms, Human | 3 | CTD_human |
| ENSG00000171791 | BCL2 | C1330966 | Developmental Academic Disorder | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C1458155 | Mammary Neoplasms | 3 | CTD_human |
| ENSG00000171791 | BCL2 | C1879321 | Acute Myeloid Leukemia (AML-M2) | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C1956130 | Lymphoma, Follicular, Grade 1 | 2 | CTD_human |
| ENSG00000171791 | BCL2 | C1956131 | Lymphoma, Follicular, Grade 3 | 2 | CTD_human |
| ENSG00000171791 | BCL2 | C1956132 | Lymphoma, Follicular, Grade 2 | 2 | CTD_human |
| ENSG00000171791 | BCL2 | C1961099 | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C2931456 | Prostate cancer, familial | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C2937358 | Cerebral Hemorrhage | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C2985290 | Fetal Alcohol Spectrum Disorders | 1 | PSYGENET |
| ENSG00000171791 | BCL2 | C3541456 | Spondyloepiphyseal Dysplasia Tarda, X-Linked | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C3714542 | Lymphoma, Diffuse | 2 | CTD_human |
| ENSG00000171791 | BCL2 | C4551479 | Schwartz-Jampel Syndrome, Type 1 | 1 | CTD_human |
| ENSG00000171791 | BCL2 | C4704874 | Mammary Carcinoma, Human | 3 | CTD_human |
| ENSG00000171791 | BCL2 | C4721532 | Lymphoma, Non-Hodgkin, Familial | 2 | CTD_human |
| ENSG00000171791 | BCL2 | C4722327 | PROSTATE CANCER, HEREDITARY, 1 | 1 | CTD_human |
